Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2005

View Archived Issues

GHRH JV-1-42 crosses blood-brain barrier, indicating possible use for malignant glioblastomas

Urigen receives IND clearance for phase IIb study of U-101

Bristol-Myers Squibb profiles recent events

Alimera and CDS begin phase III diabetic macular edema trial

pSivida to acquire Control Delivery Systems

PharmaMar's PM-02734 enters clinic

European orphan drug designation for Niprisan for sickle cell disease

Vertex refocuses pipeline priorities for 2006

Nidek to develop epinastine hydrochloride eye drops in Japan

Gentium private offering to fund pipeline development

Canadian clearance for phase II trial of Proxinium

Orphan drug status for ZymoGenetics' IL-21 for melanoma

NF-kappa B decoy oligo begins Japanese phase I study for atopic dermatitis

Remicade approved in E.U. for moderate to severe plaque psoriasis

FDA approves new indication for Aromasin

Data from nonhuman primate studies on SB-462795, an investigational drug for osteoporosis

Astellas Pharma scientists identify a novel glycogen phosphorylase inhibitor

New title added to the Drug R&D Backgrounders topic list - Rosacea

CP-744809 shows promise for treating diabetic complications

A novel XIAP inhibitor TPI-1540-14 sensitizes CLL cells to CD40-targeted therapy

CDP-323 improves clinical scores in EAE mice

Phase II data on the effects and safety of LymphoStat-B in SLE

A phase III study confirms the efficacy of lubiprostone in constipation

Update on the effects and safety of cilansetron in IBS-D

Clinical data support the use of entecavir in chronic hepatitis B

Evidence suggests the DP1 receptor may be a novel target for antiallergic therapies

Low-dose risperidone reported to improve behavior in children with autism

Recent patents cover novel agents for respiratory and other inflammatory disorders

Novel drugs for lipoprotein disorders, obesity etc. claimed in recent patents